1.The path, dilemma, and countermeasures for patients to inform their families of the breaking bad news
Fengxing ZHONG ; Xiuping YIN ; Tiantian BAI
Chinese Medical Ethics 2025;38(1):116-122
Clinically, the occurrence of the breaking bad news is inevitable. For patients, they not only need to accept and cope with bad news, but also need to inform the bad news to their families with clear thinking and appropriate language, seeking their support and cooperation. This paper analysed the connotation and informing dilemma of bad news, investigated patients’ informing tendencies, as well as evaluated the advantages and disadvantages of three disclosure methods, including concealment, immediate informing, and staged informing. On these bases, a detailed response strategy for patients to inform their families was proposed in three parts, including pre-preparation, mid-articulation, and post-summary. In the initial phase, thorough preparation is essential. During the middle stage, when delivering bad news, use plain language and help family members adjust their emotions. In the final phase, ensure that all information and viewpoints have been fully communicated. In addition, the roles and analysis steps that doctors should play were analysed from their perspective and combined with the degree of doctor-patient trust. Effective informing of bad news is not only about communication skills, but also involves a deep understanding and respect for the psychological needs of patients and their families. Through meticulous preparation, appropriate expression, emotional support, and clear confirmation, communication and trust are promoted to face and overcome difficulties together.
2.Effect of a novel cryoprotectant in tissues and cells
Qingfang WANG ; Fen ZHANG ; Guangping CHANG ; Zihan LI ; Lan XING ; Hao PENG ; Xiuping ZENG ; Guiqiang ZHONG ; Hui CHEN ; Bo LIU ; Zhenyu LIU ; Xiao LIANG
Chinese Journal of Tissue Engineering Research 2025;29(36):7816-7826
BACKGROUND:The cryopreservation technology enables tissues/cells to be stored for a long time in a low-temperature environment while maintaining the integrity of their activity and function,which is of great significance for the construction of cell therapy,tissue engineering and biological sample banks.Cryoprotective agents often contain dimethyl sulfoxide and serum.To avoid the toxic side effects of dimethyl sulfoxide,the complexity of serum components and immune responses,although some finished cryoprotective agents have been marketed,they are faced with many difficulties such as high cost and limited application.Therefore,there is an urgent need to develop a cryoprotective agent with clear components and the ability to solve the above problems.OBJECTIVE:To evaluate the effects of a novel cryoprotectant on cryopreservation efficiency of different tissue and cell sources.METHODS:By applying the novel cryoprotectant as an experimental group with the commercially available and widely used cryoprotectant(control group)to umbilical cord Wharton's jelly tissue,umbilical cord mesenchymal stem cells,umbilical cord blood/peripheral blood mononuclear cells,NK and CIK cells,comparative analyses were conducted in terms of cell morphology,number,viability,surface markers,differentiation potential,and cell-killing toxicity assay before cryopreservation and after resuscitation thawing.We confirmed the cryopreservation effect of the new cryoprotectant and its potential application value.RESULTS AND CONCLUSION:(1)The novel cryoprotectant facilitated the normal growth of cryopreserved Wharton's jelly tissue upon recovery,exhibiting mesenchymal stem cell morphology.No significant differences were observed between the experimental and control groups in terms of cell recovery rate,surface markers,and differentiation potential.(2)There was no significant difference in the number and viability of cells between the experimental group and the control group after cryopreservation of cord blood/peripheral blood mononuclear cells,and the cryo-resuscitated cell numbers and viability of derived NK cells/CIK cells did not show significant difference between the experimental and control groups.(3)For NK cells derived and differentiated from cord blood/peripheral blood mononuclear cells,there was no significant difference in the proportion of CD56+CD16+cell subpopulations between the experimental group and the control group.For CIK cells derived and differentiated from cord blood/peripheral blood mononuclear cells,there was no significant difference in the proportions of CD3+CD8+and CD3+CD56+cell subpopulations between the experimental group and the control group.(4)In terms of cytotoxicity testing,when the effective-target ratio of immune cells and melanoma cell line Mel624 was 20:1,whether it was NK cells/CIK cells derived from cord blood or peripheral blood mononuclear cells,there was no significant difference in the tumoricidal activity of cells between the experimental group and the control group.These findings suggest that the novel cryoprotectant can replace existing commercially available and widely used cryoprotectants,and is applicable to Wharton's jelly tissue,umbilical cord mesenchymal stem cells,umbilical cord blood/peripheral blood mononuclear cells,as well as NK and CIK cells,providing a solid technical foundation for the scaling,standardization,and commercialization of universal cryoprotectants.
3.A small molecule cryptotanshinone induces non-enzymatic NQO1-dependent necrosis in cancer cells through the JNK1/2/Iron/PARP/calcium pathway.
Ying HOU ; Bingling ZHONG ; Lin ZHAO ; Heng WANG ; Yanyan ZHU ; Xianzhe WANG ; Haoyi ZHENG ; Jie YU ; Guokai LIU ; Xin WANG ; Jose M MARTIN-GARCIA ; Xiuping CHEN
Acta Pharmaceutica Sinica B 2025;15(2):991-1006
Human NAD(P)H: quinone oxidoreductase 1 (NQO1) is a flavoenzyme expressed at high levels in multiple solid tumors, making it an attractive target for anticancer drugs. Bioactivatable drugs targeting NQO1, such as β-lapachone (β-lap), are currently in clinical trials for the treatment of cancer. β-Lap selectively kills NQO1-positive (NQO1+) cancer cells by inducing reactive oxygen species (ROS) via catalytic activation of NQO1. In this study, we demonstrated that cryptotanshinone (CTS), a naturally occurring compound, induces NQO1-dependent necrosis without affecting NQO1 activity. CTS selectively kills NQO1+ cancer cells by inducing NQO1-dependent necrosis. Interestingly, CTS directly binds to NQO1 but does not activate its catalytic activity. In addition, CTS enables activation of JNK1/2 and PARP, accumulation of iron and Ca2+, and depletion of ATP and NAD+. Furthermore, CTS selectively suppressed tumor growth in the NQO1+ xenograft models, which was reversed by NQO1 inhibitor and NQO1 shRNA. In conclusion, CTS induces NQO1-dependent necrosis via the JNK1/2/iron/PARP/NAD+/Ca2+ signaling pathway. This study demonstrates the non-enzymatic function of NQO1 in inducing cell death and provides new avenues for the design and development of NQO1-targeted anticancer drugs.
4.Cross-cultural adaptation, reliability, and validity of the Birth Satisfaction Scale-Revised
Xiaoying ZHONG ; Martin Colin R. ; Xixi LI ; Xiujing GUO ; Dehua LI ; Bangjun WANG ; Xiuping LIU
Chinese Journal of Practical Nursing 2025;41(17):1330-1337
Objective:To translate the Birth Satisfaction Scale-Revised (BSS-R) into Chinese and assesses the psychometric properties of this tool.Methods:Following the Beaton cross-cultural adaptation guidelines, the Chinese version of BSS-R was formed through forward translation, back translation, expert consultation, and pre-testing. The present study was conducted in a sample of 347 women took part between 6-8 weeks postpartum, from the postpartum clinics of two tertiary hospitals in Sichuan province.Results:Totally 340 questionnaires were effectively collected with a majority of respondents aged 30-39 accounting for 64.7% of the total. The Chinese version of BSS-R comprises 10 items, which were classified into three domains as stress experienced during labour, women′s personal attributes, and quality of care provision. The Cronbach α coefficient was 0.745 for the total scale and ranged from 0.523 to 0.738 for sub-scales. The split-half reliability was 0.746 for the total scale, and ranged from 0.523 to 0.733 for sub-scales. Exploratory factor analysis revealed the presence of three components with eigen values greater than 1, explaining a total variance of 58.868%. The fit indices showed that the original correlated three factor model of Chinese version of BSS-R was adequate.Conclusions:The Chinese version of BSS-R can be considered a clear, easily understandable and convenient tool for assessing the women′s birth satisfaction in Chinese cultural context.
5.Effect of a novel cryoprotectant in tissues and cells
Qingfang WANG ; Fen ZHANG ; Guangping CHANG ; Zihan LI ; Lan XING ; Hao PENG ; Xiuping ZENG ; Guiqiang ZHONG ; Hui CHEN ; Bo LIU ; Zhenyu LIU ; Xiao LIANG
Chinese Journal of Tissue Engineering Research 2025;29(36):7816-7826
BACKGROUND:The cryopreservation technology enables tissues/cells to be stored for a long time in a low-temperature environment while maintaining the integrity of their activity and function,which is of great significance for the construction of cell therapy,tissue engineering and biological sample banks.Cryoprotective agents often contain dimethyl sulfoxide and serum.To avoid the toxic side effects of dimethyl sulfoxide,the complexity of serum components and immune responses,although some finished cryoprotective agents have been marketed,they are faced with many difficulties such as high cost and limited application.Therefore,there is an urgent need to develop a cryoprotective agent with clear components and the ability to solve the above problems.OBJECTIVE:To evaluate the effects of a novel cryoprotectant on cryopreservation efficiency of different tissue and cell sources.METHODS:By applying the novel cryoprotectant as an experimental group with the commercially available and widely used cryoprotectant(control group)to umbilical cord Wharton's jelly tissue,umbilical cord mesenchymal stem cells,umbilical cord blood/peripheral blood mononuclear cells,NK and CIK cells,comparative analyses were conducted in terms of cell morphology,number,viability,surface markers,differentiation potential,and cell-killing toxicity assay before cryopreservation and after resuscitation thawing.We confirmed the cryopreservation effect of the new cryoprotectant and its potential application value.RESULTS AND CONCLUSION:(1)The novel cryoprotectant facilitated the normal growth of cryopreserved Wharton's jelly tissue upon recovery,exhibiting mesenchymal stem cell morphology.No significant differences were observed between the experimental and control groups in terms of cell recovery rate,surface markers,and differentiation potential.(2)There was no significant difference in the number and viability of cells between the experimental group and the control group after cryopreservation of cord blood/peripheral blood mononuclear cells,and the cryo-resuscitated cell numbers and viability of derived NK cells/CIK cells did not show significant difference between the experimental and control groups.(3)For NK cells derived and differentiated from cord blood/peripheral blood mononuclear cells,there was no significant difference in the proportion of CD56+CD16+cell subpopulations between the experimental group and the control group.For CIK cells derived and differentiated from cord blood/peripheral blood mononuclear cells,there was no significant difference in the proportions of CD3+CD8+and CD3+CD56+cell subpopulations between the experimental group and the control group.(4)In terms of cytotoxicity testing,when the effective-target ratio of immune cells and melanoma cell line Mel624 was 20:1,whether it was NK cells/CIK cells derived from cord blood or peripheral blood mononuclear cells,there was no significant difference in the tumoricidal activity of cells between the experimental group and the control group.These findings suggest that the novel cryoprotectant can replace existing commercially available and widely used cryoprotectants,and is applicable to Wharton's jelly tissue,umbilical cord mesenchymal stem cells,umbilical cord blood/peripheral blood mononuclear cells,as well as NK and CIK cells,providing a solid technical foundation for the scaling,standardization,and commercialization of universal cryoprotectants.
6.Cross-cultural adaptation, reliability, and validity of the Birth Satisfaction Scale-Revised
Xiaoying ZHONG ; Martin Colin R. ; Xixi LI ; Xiujing GUO ; Dehua LI ; Bangjun WANG ; Xiuping LIU
Chinese Journal of Practical Nursing 2025;41(17):1330-1337
Objective:To translate the Birth Satisfaction Scale-Revised (BSS-R) into Chinese and assesses the psychometric properties of this tool.Methods:Following the Beaton cross-cultural adaptation guidelines, the Chinese version of BSS-R was formed through forward translation, back translation, expert consultation, and pre-testing. The present study was conducted in a sample of 347 women took part between 6-8 weeks postpartum, from the postpartum clinics of two tertiary hospitals in Sichuan province.Results:Totally 340 questionnaires were effectively collected with a majority of respondents aged 30-39 accounting for 64.7% of the total. The Chinese version of BSS-R comprises 10 items, which were classified into three domains as stress experienced during labour, women′s personal attributes, and quality of care provision. The Cronbach α coefficient was 0.745 for the total scale and ranged from 0.523 to 0.738 for sub-scales. The split-half reliability was 0.746 for the total scale, and ranged from 0.523 to 0.733 for sub-scales. Exploratory factor analysis revealed the presence of three components with eigen values greater than 1, explaining a total variance of 58.868%. The fit indices showed that the original correlated three factor model of Chinese version of BSS-R was adequate.Conclusions:The Chinese version of BSS-R can be considered a clear, easily understandable and convenient tool for assessing the women′s birth satisfaction in Chinese cultural context.
7.Current status of cognition and skin care behavior in adolescent patients with acne: A survey in China.
Jing TIAN ; Hong SHU ; Qiufang QIAN ; Zhong SHEN ; Chunyu ZHAO ; Li SONG ; Ping LI ; Xiuping HAN ; Hua QIAN ; Jinping CHEN ; Hua WANG ; Lin MA ; Yuan LIANG
Chinese Medical Journal 2024;137(4):476-477
8.Family participation in respiratory rehabilitation on the treatment compliance and outcomes in the patients with chronic obstructive pulmonary disease
Qiuxuan ZENG ; Xiuping ZHONG ; Fenxi LIANG ; Qiuhong LI ; Yucui GONG
Chinese Journal of Modern Nursing 2019;25(14):1732-1734
Objective? To explore the effects of family participation in the respiratory rehabilitation of the patients with chronic obstructive pulmonary disease (COPD) in terms of their treatment compliance and outcomes. Methods? Totally 80 COPD patients admitted in The First Affiliated Hospital of Guangzhou Medical University from March 2016 to August 2017 were selected and divided into the control group (n=40) and the observation group (n=40) according to the random number table. Patients in the control group received conventional respiratory rehabilitation intervention, while the patients had their family members participated in the rehabilitation process in the observation group. Treatment compliance and effects were compared between the two groups. Results? The compliance of the observation group totaled 97.50%, while that of the control group totaled 87.50% (χ2=7.207, P< 0.05). After 3 months' intervention, the walking distance within 6 min of the observation group was (278.72±45.89) m; the PEF pred% was (93.46±13.47)%; and FEV1% was (87.42±14.71)%, better than those of the control group (t=4.127,7.156,3.859;P< 0.05). Conclusions? Family participation in respiratory rehabilitation process can improve the compliance of COPD patients significantly, thus improve the treatment effects, which is worth promoting in clinical practice.
9.Toxic epidermal necrolysis induced by mouse nerve growth factor for injection
Daimei WANG ; Ereyi ZHAO ; Jingbo ZHONG ; Fangxuan HAN ; Xiuping LYU
Adverse Drug Reactions Journal 2019;21(4):311-312
A 22﹣year﹣old female patient received methylprednisolone sodium succinate( methyl﹣prednisolone)for injection( 1 000 mg/d for 3 days and gradually reduced to 60 mg/d for maintenance therapy,IV infusion),immunoglobulin( 20 g/d,IV infusion),mouse nerve growth factor( 20 μg/d, intramuscular injection),vitamin B1(100 mg/d,intramuscular injection),and mecobalamin(1 mg/d,IV injection)for multiple sclerosis. Twelve days later,mouse nerve growth factor was temporarily discontinued and 7 days later,the drug was given again. On day 2 of retreatment,the patient developed conjunctival congestion. On day 3 of retreatment,red spots appeared on her chest,back,abdomen,and forearms. Then the rashes gradually increased,linked into pieces,and spread all over the body. Rashes partly formed blisters,blisters ulcerated,and epidermis exfoliated. It was considered that mouse nerve growth factor induced the toxic epidermal necrolysis. Then the drug was discontinued,the dose of methylprednisolone was increased to 500 mg/d,and at the same time,immunoglobulin,desloratadine,and fexofenadine were given. Twenty days later,the rashes subsided and pigmentation remained.
10.Toxic epidermal necrolysis induced by mouse nerve growth factor for injection
Daimei WANG ; Ereyi ZHAO ; Jingbo ZHONG ; Fangxuan HAN ; Xiuping LYU
Adverse Drug Reactions Journal 2019;21(4):311-312
A 22﹣year﹣old female patient received methylprednisolone sodium succinate( methyl﹣prednisolone)for injection( 1 000 mg/d for 3 days and gradually reduced to 60 mg/d for maintenance therapy,IV infusion),immunoglobulin( 20 g/d,IV infusion),mouse nerve growth factor( 20 μg/d, intramuscular injection),vitamin B1(100 mg/d,intramuscular injection),and mecobalamin(1 mg/d,IV injection)for multiple sclerosis. Twelve days later,mouse nerve growth factor was temporarily discontinued and 7 days later,the drug was given again. On day 2 of retreatment,the patient developed conjunctival congestion. On day 3 of retreatment,red spots appeared on her chest,back,abdomen,and forearms. Then the rashes gradually increased,linked into pieces,and spread all over the body. Rashes partly formed blisters,blisters ulcerated,and epidermis exfoliated. It was considered that mouse nerve growth factor induced the toxic epidermal necrolysis. Then the drug was discontinued,the dose of methylprednisolone was increased to 500 mg/d,and at the same time,immunoglobulin,desloratadine,and fexofenadine were given. Twenty days later,the rashes subsided and pigmentation remained.

Result Analysis
Print
Save
E-mail